Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...
The FDA approved the use of pembrolizumab (Keytruda; Merck) and berahyaluronidase alfa-pmph (Keytruda Qlex; Merck) for use in patients 12 years and older with solid tumor indications approved for the ...
Subcutaneous pembrolizumab has been approved across all indications, cutting chair and administration times with a median ...
Merck & Co. Inc. (NYSE:MRK) is one of the best value stocks in Goldman Sachs’ portfolio. On September 19, the company ...
Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately to severely ...
The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.
The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab ...
Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers. The Food and Drug Administration (FDA) approved ...
One year into treatment with an every-6-month dose of the investigational drug lenacapavir (LEN, Gilead Sciences) in a dual-treatment combination, 88% of treatment-naive people living with HIV had ...
When Eli Lilly gained emergency use approval for its COVID-19 antibody treatment last October, it was a major triumph for a company aiming to satisfy a desperate need around the world. But eight ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback